Degron Partners Molecular Glue Degraders with Takeda in $1.2 Billion Deal

Shanghai Degron Therapeutics will use its molecular glue-based targeted protein degradation drug discovery platform to identify multiple targets in oncology, neuroscience, and inflammation for Japan’s Takeda. The Chinese company will receive an upfront payment and is eligible to receive potential milestone payments that could total $1.2 billion. Degron will apply its GlueXplorer platform to identify molecular glue degraders for therapeutic targets selected by Takeda. Upon reaching a specified stage of advancement, the projects will be sent to Takeda for further development and commercialization. Degron will also receive royalty payments on sales, and Takeda will make an investment of unspecified size in Degron. More details....

Share this with colleagues: